Return on Capital (ROC)
Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
Eli Lilly & Co., ROIC calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | 8,466,038) | 3,090,452) | 4,320,468) | 5,040,358) | 6,357,340) | |
| Invested capital2 | 35,800,600) | 29,384,700) | 24,302,500) | 26,139,800) | 24,557,100) | |
| Performance Ratio | ||||||
| ROIC3 | 23.65% | 10.52% | 17.78% | 19.28% | 25.89% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | 6.59% | 4.83% | 14.05% | 12.89% | 4.30% | |
| Amgen Inc. | 8.51% | 11.15% | 16.11% | 15.93% | 20.35% | |
| Bristol-Myers Squibb Co. | — | 8.69% | 6.37% | 8.29% | -7.57% | |
| Danaher Corp. | — | 3.94% | 8.76% | 9.01% | 7.43% | |
| Gilead Sciences Inc. | — | 11.75% | 8.28% | 14.43% | 1.26% | |
| Johnson & Johnson | 10.76% | 8.98% | 14.16% | 19.23% | 13.97% | |
| Merck & Co. Inc. | — | -1.02% | 19.14% | 18.87% | 11.66% | |
| Pfizer Inc. | — | -0.82% | 28.01% | 20.98% | 5.87% | |
| Regeneron Pharmaceuticals Inc. | 26.67% | 23.53% | 28.87% | 72.50% | 43.95% | |
| Thermo Fisher Scientific Inc. | — | 5.98% | 7.76% | 9.32% | 10.70% | |
| Vertex Pharmaceuticals Inc. | — | 19.93% | 22.66% | 23.86% | 37.13% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2024 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 8,466,038 ÷ 35,800,600 = 23.65%
4 Click competitor name to see calculations.
| Performance ratio | Description | The company |
|---|---|---|
| ROIC | A measure of the periodic, after tax, cash-on-cash yield earned in the business. | Eli Lilly & Co. ROIC deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Decomposition of ROIC
Eli Lilly & Co., decomposition of ROIC
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The primary reason for the increase in return on invested capital (ROIC) over 2024 year is the increase in profitability measured by operating profit margin (OPM) ratio.
Operating Profit Margin (OPM)
Eli Lilly & Co., OPM calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | 8,466,038) | 3,090,452) | 4,320,468) | 5,040,358) | 6,357,340) | |
| Add: Cash operating taxes2 | 4,911,605) | 3,731,159) | 2,811,147) | 1,446,213) | 1,244,662) | |
| Net operating profit before taxes (NOPBT) | 13,377,644) | 6,821,611) | 7,131,615) | 6,486,571) | 7,602,002) | |
| Revenue | 45,042,700) | 34,124,100) | 28,541,400) | 28,318,400) | 24,539,800) | |
| Profitability Ratio | ||||||
| OPM3 | 29.70% | 19.99% | 24.99% | 22.91% | 30.98% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | 10.48% | 14.58% | 26.77% | 27.06% | 13.19% | |
| Amgen Inc. | 24.36% | 40.00% | 35.35% | 32.55% | 38.71% | |
| Bristol-Myers Squibb Co. | — | 21.81% | 19.38% | 20.31% | -12.65% | |
| Danaher Corp. | — | 21.44% | 27.12% | 27.65% | 23.43% | |
| Gilead Sciences Inc. | — | 29.07% | 25.11% | 34.43% | 10.83% | |
| Johnson & Johnson | 18.19% | 17.15% | 22.67% | 24.39% | 20.20% | |
| Merck & Co. Inc. | — | 4.63% | 30.22% | 30.60% | 19.13% | |
| Pfizer Inc. | — | 1.43% | 38.86% | 30.18% | 19.53% | |
| Regeneron Pharmaceuticals Inc. | 30.25% | 29.03% | 39.28% | 57.80% | 45.28% | |
| Thermo Fisher Scientific Inc. | — | 15.91% | 18.33% | 23.79% | 24.12% | |
| Vertex Pharmaceuticals Inc. | — | 38.69% | 46.55% | 36.91% | 50.94% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
OPM = 100 × NOPBT ÷ Revenue
= 100 × 13,377,644 ÷ 45,042,700 = 29.70%
4 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| OPM | The operating profit margin (OPM) is the ratio of pretax economic earnings, or NOPBT, to sales. | Eli Lilly & Co. OPM deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Turnover of Capital (TO)
Eli Lilly & Co., TO calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenue | 45,042,700) | 34,124,100) | 28,541,400) | 28,318,400) | 24,539,800) | |
| Invested capital1 | 35,800,600) | 29,384,700) | 24,302,500) | 26,139,800) | 24,557,100) | |
| Efficiency Ratio | ||||||
| TO2 | 1.26 | 1.16 | 1.17 | 1.08 | 1.00 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | 0.81 | 0.80 | 0.71 | 0.59 | 0.44 | |
| Amgen Inc. | 0.51 | 0.38 | 0.62 | 0.60 | 0.63 | |
| Bristol-Myers Squibb Co. | — | 0.67 | 0.64 | 0.58 | 0.47 | |
| Danaher Corp. | — | 0.30 | 0.40 | 0.40 | 0.34 | |
| Gilead Sciences Inc. | — | 0.59 | 0.59 | 0.57 | 0.48 | |
| Johnson & Johnson | 0.83 | 0.86 | 0.83 | 0.96 | 0.84 | |
| Merck & Co. Inc. | — | 0.86 | 0.80 | 0.69 | 0.84 | |
| Pfizer Inc. | — | 0.38 | 0.91 | 0.93 | 0.40 | |
| Regeneron Pharmaceuticals Inc. | 1.14 | 1.10 | 0.99 | 1.48 | 1.03 | |
| Thermo Fisher Scientific Inc. | — | 0.50 | 0.54 | 0.49 | 0.53 | |
| Vertex Pharmaceuticals Inc. | — | 0.75 | 0.68 | 0.81 | 0.76 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Invested capital. See details »
2 2024 Calculation
TO = Revenue ÷ Invested capital
= 45,042,700 ÷ 35,800,600 = 1.26
3 Click competitor name to see calculations.
| Efficiency ratio | Description | The company |
|---|---|---|
| TO | The turnover of capital (TO) is the ratio of sales to invested capital. Capital turnover is a function of the efficiency of working capital management and of net fixed assets. | Eli Lilly & Co. TO deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Effective Cash Tax Rate (CTR)
Eli Lilly & Co., CTR calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | 8,466,038) | 3,090,452) | 4,320,468) | 5,040,358) | 6,357,340) | |
| Add: Cash operating taxes2 | 4,911,605) | 3,731,159) | 2,811,147) | 1,446,213) | 1,244,662) | |
| Net operating profit before taxes (NOPBT) | 13,377,644) | 6,821,611) | 7,131,615) | 6,486,571) | 7,602,002) | |
| Tax Rate | ||||||
| CTR3 | 36.72% | 54.70% | 39.42% | 22.30% | 16.37% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | 22.68% | 58.42% | 25.72% | 18.70% | 26.24% | |
| Amgen Inc. | 31.09% | 27.52% | 27.01% | 18.93% | 15.91% | |
| Bristol-Myers Squibb Co. | — | 40.21% | 48.91% | 29.34% | — | |
| Danaher Corp. | — | 39.60% | 19.69% | 18.58% | 7.07% | |
| Gilead Sciences Inc. | — | 31.23% | 44.33% | 25.84% | 76.01% | |
| Johnson & Johnson | 29.05% | 39.03% | 25.14% | 17.53% | 17.68% | |
| Merck & Co. Inc. | — | 125.66% | 20.99% | 10.42% | 27.35% | |
| Pfizer Inc. | — | 252.75% | 20.44% | 25.02% | 25.53% | |
| Regeneron Pharmaceuticals Inc. | 22.67% | 26.07% | 26.00% | 15.19% | 5.43% | |
| Thermo Fisher Scientific Inc. | — | 24.94% | 21.94% | 19.99% | 15.79% | |
| Vertex Pharmaceuticals Inc. | — | 30.87% | 28.16% | 19.91% | 4.34% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 4,911,605 ÷ 13,377,644 = 36.72%
4 Click competitor name to see calculations.
| Tax rate | Description | The company |
|---|---|---|
| CTR | Effective cash tax rate on operating income. | Eli Lilly & Co. CTR increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |